DUBLIN--(BUSINESS WIRE)--The "World Market for Precision Cancer Diagnostic Tests" report has been added to ResearchAndMarkets.com's offering.
World Market for Precision Cancer Diagnostic Tests, a market-based and industry-focused report, examines the global market environment for precision cancer testing products and procedures, including the following data:
- Market for Precision Cancer Testing, IVD and Imaging, 2018-2023
- Global Precision Cancer Diagnostic Testing Product Demand by Type & Geographical Market, 2018-2023
-
Precision Cancer Diagnostic Testing Procedural Volume by Type,
2018-2023
- Global Precision Cancer Diagnostic Testing Procedures by Type, 2018-2023
Procedures & Products
The volume of precision cancer-related procedures is projected to rise. Several trends and factors will influence growth. Advances in imaging and molecular technologies will lead to the introduction of new tests with enhanced tumor specificity and sensitivity.
The upgrading and modernization of medical delivery systems in many countries will make more funding available for cancer care. An increasing emphasis on preventive medicine in global healthcare will boost demand for tests that enable the early detection of tumors.
Geographic Markets
The size and growth potential of geographical markets for precision cancer diagnostic procedures and products vary widely from country to country due to differences in demographic patterns, lifestyles trends, health insurance coverage, healthcare spending intensity, medical delivery systems, patient care approaches, and price controls.
Based on a high level of national health expenditures and patient activity, the US market will remain the largest and most diversified.
Industry Structure
The global precision cancer diagnostics segment includes approximately 300 participants, ranging in size from small, narrowly focused firms to large, diversified multinational companies. Since precision cancer diagnostics serve health care applications, they are subject to strict government regulations and serve highly price-sensitive markets.
Overall success in the industry requires an effective balancing of research and development productivity, manufacturing efficiencies, effective marketing and distribution, and responsive customer service.
World Market for Precision Cancer Diagnostic Tests explores the activities of selected companies involved in the segment to serve as a representative sample of competitors active in the business.
Included in the demand estimates and forecasts that appear in this report are the value of reagents and other consumables employed directly in precision cancer procedures and a percentage of the value of instruments and systems purchased by end users.
This percentage reflects the portion of total IVD and imaging tests that involve cancer-related applications. The analysis covers commercially sold and distributed tests only. Laboratory-developed tests (LDTs) and tests used for research purposes are excluded from the discussion.
Key Topics Covered
1. Executive Summary
2. Market Environment
3. Cancer Statistics
4. Procedures & Products
5. Geographic Markets
6. Industry Structure
Company Profiles
- Abbott Laboratories
- Agilent Technologies, Inc.
- Angle plc
- Becton Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biocartis N.V.
- Biocept, Inc.
- bioMerieux SA
- Canon Medical Systems Corporation
- Cynvenio Biosystems, Inc.
- Danaher Corporation
- Epigenomics AG
- Exact Sciences Corporation
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc.
- General Electric Company
- Genomic Health, Inc.
- Hologic, Inc.
- Illumina, Inc.
- Menarini Silicon Biosystems SpA
- Myriad Genetics, Inc.
- NanoString Technologies, Inc.
- Ortho Clinical Diagnostics
- QIAGEN N.V.
- Randox Laboratories Ltd.
- Roche Holding AG
- Royal Philips N.V.
- Medical Imaging
- Digital Pathology
- Siemens AG
- Thermo Fisher Scientific
- Vela Diagnostics
For more information about this report visit https://www.researchandmarkets.com/research/dkq6rn/world_market_for?w=4
